Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (CHEK) covers the period ending December 31, 2024. The registrant is a foreign private issuer based in Isfiya, Israel, reporting a material event regarding its listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding share price.
Material Changes
The primary material change is the receipt of a deficiency notice from Nasdaq on December 31, 2024. The Company failed to maintain the Minimum Bid Price Requirement of $1.00 per share for 30 consecutive business days (November 8, 2024, to December 20, 2024).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period ending June 30, 2025, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days during the compliance period.
- Delisting Risk: If the deficiency is not cured by the end of the initial period, the Company may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares). Failure to cure the deficiency ultimately subjects the ordinary shares to delisting.
- Trading Status: The notice has no immediate effect on trading; shares will continue to trade on Nasdaq under the symbol "CHEK" during the compliance period.
Investor Verification Checklist
- Verify the current closing bid price of Check-Cap Ltd. shares to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading at or above $1.00 before June 30, 2025.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first is unsuccessful.
- Check for any subsequent filings regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.